市場調查報告書
商品編碼
1321866
全球免疫腫瘤精準醫學市場(2023-2030):最終用戶、癌症類型、治療類型和生物標記的規模、佔有率、成長分析和預測Global Precision Immuno-Oncology Market Size, Share, Growth Analysis, By End use, By Cancer type, By Treatment type, By Biomarker - Industry Forecast 2023-2030 |
全球免疫腫瘤精準醫療市場規模預計將從2021年的494億美元成長到2022年的547.4億美元,預測期內年複合成長率為10.8%,到2030年將達到1243.3億美元。 。
全球癌症免疫精準醫學是癌症治療中一個先進且有前景的領域,利用精準和個性化的方法來靶向和根除癌細胞。這種創新方法將免疫療法和精準醫學相結合,旨在提高癌症治療的療效,同時最大限度地減少副作用。新一代測序和生物標記分析等尖端技術在識別特定腫瘤特徵和指導治療決策方面發揮著重要作用。隨著持續的研究和臨床試驗,免疫腫瘤學精準醫學具有巨大的潛力,可以徹底改變癌症治療並改善全世界患者的治療結果。
癌症患病率的不斷上升預計將推動對免疫腫瘤學精準醫療的需求。隨著癌症患者數量的持續成長,人們越來越需要更有效、更有針對性的治療方案。癌症免疫精準醫學提供了根據特定腫瘤特徵和免疫反應為個體患者量身定做癌症治療的可能性。利用免疫系統的力量來對抗癌症,這一新興領域有望改善治療結果並應對不同類型癌症帶來的挑戰。
免疫腫瘤學擴大使用聯合療法與傳統癌症治療(例如化療和放療)一起使用。這種方法因其提高治療效果和對抗治療耐藥性的潛力而受到歡迎。例如,免疫療法和化療的結合在治療某些癌症類型(例如肺癌和黑色素瘤)方面顯示出有希望的結果。化療可以縮小腫瘤,但免疫療法可以幫助患者的免疫系統識別癌細胞並更有效地攻擊它們。
在本報告中,我們研究了全球癌症免疫精準醫學市場,提供了市場概況,分析了市場的各種影響因素、技術和創新趨勢、監管環境、市場規模的轉變和預測以及各個細分市場及地區、細分、競爭格局、主要企業概況等。
Market Insights
Global Precision Immuno-Oncology Market size was valued at USD 49.4 billion in 2021 and is poised to grow from USD 54.74 billion in 2022 to USD 124.33 billion by 2030, growing at a CAGR of 10.8% in the forecast period (2023-2030).
Global Precision Immuno-Oncology is an advanced and promising field in cancer treatment, utilizing precise and personalized approaches to target and eradicate cancer cells. By combining immunotherapy with precision medicine, this innovative approach aims to enhance the effectiveness of cancer treatment while minimizing side effects. Cutting-edge technologies, such as next-generation sequencing and biomarker analysis, play a crucial role in identifying specific tumor characteristics and guiding treatment decisions. With ongoing research and clinical trials, Precision Immuno-Oncology holds great potential in revolutionizing cancer care and improving patient outcomes worldwide.
Top-down and bottom-up approaches were used to estimate and validate the size of Precision Immuno-Oncology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Precision Immuno-Oncology Market Segmental Analysis
Precision Immuno-Oncology Market is segmented on the basis of Treatment type, cancer type, end-user, biomarker, and region. By end use, the Precision Immuno-Oncology Market is segmented into hospitals, clinics, research institutes, and others. By cancer type, the Precision Immuno-Oncology Market is segmented into Lung cancer, Breast cancer, Prostate cancer, Melanoma, and others. By treatment type, the Precision Immuno-Oncology Market is segmented into immune checkpoint inhibitors, car T cell therapy, cancer vaccines, and others. By biomarker, the Precision Immuno-Oncology Market is segmented into PD-L1, BRCA, KRAS, EGFR, and others. By region, the Precision Immuno-Oncology Market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Driver
The increasing prevalence of cancer is expected to drive the demand for Precision Immuno-Oncology. As cancer cases continue to rise, there is a growing need for more effective and targeted treatment options. Precision Immuno-Oncology offers the potential to tailor cancer therapies to individual patients based on their specific tumor characteristics and immune responses. By harnessing the power of the immune system to fight cancer, this emerging field holds promise in improving treatment outcomes and addressing the challenges posed by various types of cancer.
Restraints
The growth of the Global Precision Immuno-Oncology market is impeded by the significant cost associated with its implementation. The advanced technologies and personalized nature of precision immuno-oncology therapies can be financially challenging for both healthcare providers and patients. The high cost of treatments may limit accessibility and adoption, hindering the market's potential growth. Addressing these cost-related challenges through research, development, and innovative pricing strategies will be crucial to overcome this restraint and unlock the full potential of precision immuno-oncology in cancer treatment.
Market Trends
In precision immuno-oncology treatments is the increasing utilization of combination therapies alongside traditional cancer treatments like chemotherapy and radiation therapy. This approach has gained popularity due to its potential to enhance treatment effectiveness and combat treatment resistance. For instance, the combination of immunotherapy and chemotherapy has shown promising outcomes in treating certain cancer types like lung cancer and melanoma. While chemotherapy reduces tumor size, immunotherapy helps the patient's immune system recognize and attack cancer cells more effectively.